Children's Oncology Group's 2023 blueprint for research: Pharmacy

Authors

Andrew R. Ostrenga, Department of Pharmacy, University of Mississippi Medical Center, Children's of Mississippi, Jackson, Mississippi, USA.
Jennifer Thackray, Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ha-Mill H. McLearan, Department of Pharmacy, University of California Davis Medical Center and Children's Hospital, Sacramento, California, USA.
Kevin M. Mulieri, Department of Pharmacy, Penn State Children's Hospital, Hershey, Pennsylvania, USA.
Elizabeth Bisaccia, Advocate Aurora HealthFollow
Olga Militano, Study Development Office, Children's Oncology Group, Monrovia, California, USA.
L Lee Dupuis, Department of Pharmacy, The Hospital for Sick Children, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
M Brooke Bernhardt, Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Texas Children's Cancer and Hematology Center, Houston, Texas, USA.

Recommended Citation

Ostrenga AR, Thackray J, McLearan HH, et al. Children's Oncology Group's 2023 blueprint for research: Pharmacy. Pediatr Blood Cancer. 2023;70 Suppl 6:e30581. doi:10.1002/pbc.30581

Affiliations

Advocate Children's Hospital-Park Ridge

Abstract

Children's Oncology Group (COG) pharmacists and pharmacy technicians from more than 200 COG-member institutions comprise the COG Pharmacy Discipline. Discipline members serve an essential role in the design and execution of COG clinical trials. Core activities include study drug management, study drug access, clinical trial operations, protocol harmonization, and direct patient care. Discipline members are also actively involved in continuing education, membership engagement, and research across other COG committees/domains. Future areas of committed growth for the discipline include pharmacogenomics, pharmacokinetics, pharmacoeconomics, pharmaceutics, and implementation science.

Document Type

Article

PubMed ID

37460409